08:08 AM EDT, 09/30/2024 (MT Newswires) -- Altimmune ( ALT ) said Monday it completed patient enrollment for its phase 2b trial evaluating the safety and efficacy of pemvidutide in around 190 subjects with metabolic dysfunction-associated steatohepatitis.

Topline efficacy data is expected in Q2 2025, Altimmune ( ALT ) said, adding that it plans to file investigational new drug applications for up to three additional indications for the drug candidate in Q4.

Shares of Altimmune ( ALT ) rose 2% in recent Monday premarket activity.

Price: 6.60, Change: +0.13, Percent Change: +2.01